Stevanato Group SPA (Stevanato Group SPA) Total Liabilities : $959 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA Total Liabilities?

Stevanato Group SPA's Total Liabilities for the quarter that ended in Mar. 2024 was $959 Mil.

Stevanato Group SPA's quarterly Total Liabilities increased from Sep. 2023 ($886.09 Mil) to Dec. 2023 ($1,023.92 Mil) but then declined from Dec. 2023 ($1,023.92 Mil) to Mar. 2024 ($959.03 Mil).

Stevanato Group SPA's annual Total Liabilities increased from Dec. 2021 ($652.18 Mil) to Dec. 2022 ($703.17 Mil) and increased from Dec. 2022 ($703.17 Mil) to Dec. 2023 ($1,023.92 Mil).

Stevanato Group SPA Total Liabilities Historical Data

The historical data trend for Stevanato Group SPA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA Total Liabilities Chart

Stevanato Group SPA Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

685.27

800.29

652.18

703.17

1,023.92

Stevanato Group SPA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial													762.99	817.86	886.09	1,023.92	959.03

Stevanato Group SPA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Stevanato Group SPA's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	626.377	+	(278.245	+	57.729
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	53.481	+	8.084)
	=	1,024

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2259.081	-	1235.165
	=	1,024

Stevanato Group SPA's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	530.665	+	(304.93	+	15.25
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	100.138	+	8.051)
	=	959

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	2405.15	-	1446.116
	=	959

Stevanato Group SPA Total Liabilities Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Stevanato Group SPA (Stevanato Group SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

87N:Germany

Address

Via Molinella 17, Piombino Dese, Padua, ITA, 35017

Website

https://www.stevanatogroup.com

Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.